Galapagos NV (GLPG)
| Market Cap | 1.87B |
| Revenue (ttm) | 1.31B |
| Net Income (ttm) | 376.76M |
| Shares Out | 65.90M |
| EPS (ttm) | 5.72 |
| PE Ratio | 4.96 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 139,878 |
| Open | 28.50 |
| Previous Close | 28.47 |
| Day's Range | 28.27 - 28.71 |
| 52-Week Range | 24.74 - 37.78 |
| Beta | 0.15 |
| Analysts | Buy |
| Price Target | 36.50 (+28.39%) |
| Earnings Date | May 6, 2026 |
About GLPG
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple ... [Read more]
Financial Performance
In 2025, Galapagos NV's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for GLPG stock is "Buy." The 12-month stock price target is $36.5, which is an increase of 28.39% from the latest price.
News
Galapagos NV Transcript: Collaboration
Galapagos and Gilead entered a partnership to co-develop Gamgertamig for autoimmune diseases, sharing costs and leveraging each other's strengths. The deal unlocks $500 million for Galapagos to pursue further R&D or strategic transactions, while integrating Ouro’s team and pipeline. Registrational studies are planned for 2027.
Galapagos Enters Framework Agreement With Gilead In Connection With Ouro Deal
(RTTNews) - Galapagos (GLPG, GLPG.AS) has entered into a binding agreement with Gilead Sciences (GILD) in connection with Gilead's agreement to acquire all of the outstanding equity interests of Ouro ...
Galapagos NV: Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaini...
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining...
Galapagos NV: Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings
Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) today published its annual report for the financial year 2025 and announced that its Ann...
Galapagos NV: Galapagos Announces Nomination of Gino Santini to its Board of Directors
Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine Mr. Santini will bring extensive corporate governance, business development a...
Galapagos Announces Nomination of Gino Santini to its Board of Directors
Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine
Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings
Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information — Galapagos NV (Euronext & NASDAQ: GLPG) today published its annual report for the financial year 2025 and announced that its Annual...
Galapagos NV: Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms ...
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines
Galapagos NV: Galapagos Receives Transparency Notification from Bank of America
Mechelen, Belgium; March 117, 2026, 22:01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America. Pursuant to Belgian transpar...
Galapagos Receives Transparency Notification from Bank of America
Mechelen, Belgium ; March 117, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America.
Galapagos Receives Transparency Notifications from Bank of America
Mechelen, Belgium ; March 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.
Galapagos Creates New Subscription Right Plan
Mechelen, Belgium; March 6, 2026, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,750,000 subscription rights under a ne...
Galapagos Appoints Tania Philipp as Chief Human Resources Officer
Seasoned Life Sciences Executive Joins Galapagos with Strong Track Record in Change Management Mechelen, Belgium; March 5, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announced the ...
Galapagos NV Earnings Call Transcript: Q4 2025
2025 saw a strategic pivot, with a strong cash position, major restructuring, and a focus on business development. Operating profit rebounded due to deferred income recognition, and the company expects to be cash flow neutral or positive by end-2026.
Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Mechelen, Belgium; February 23, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the full year 2025 and provided an update on th...
Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities
Mechelen, Belgium ; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities ha...
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell the...
Galapagos NV Transcript: Jefferies London Healthcare Conference 2025
A major transformation is underway, with a strategic exit from cell therapy and a focus on redeploying €3 billion in cash into de-risked immunology and oncology assets. Key catalysts ahead include the cell therapy wind down, TIC2 phase 2 data, and new business development deals.
Galapagos NV Earnings Call Transcript: Q3 2025
Announced wind down of the cell therapy business after failed sale, incurring major impairments and restructuring costs. Focus shifts to business development, leveraging a strong cash position and Gilead partnership to pursue de-risked opportunities in oncology and immunology.
Galapagos to Present New Data from Cell Therapy Program at ASH 2025
Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors
Mechelen, Belgium ; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG36...
Biotech firm Galapagos to wind down cell therapy business
Biotechnology firm Galapagos said on Tuesday it would wind down its cell therapy business after attempts to sell it were unsuccessful, affecting 365 jobs in Europe, China and the U.S.
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos